Modafinil

A prescription wakefulness-promoting drug developed for narcolepsy, shift-work disorder, and sleep apnea. Widely used off-label as a cognitive enhancer, particularly for sustained attention under sleep deprivation.

Modafinil is an atypical dopamine-transporter inhibitor: it blocks the same transporter amphetamine acts on, and a PET study in healthy men measured roughly 39-54% occupancy of it at therapeutic exposure — real dopaminergic activity, not a negligible amount. It also acts on histamine, orexin and noradrenaline systems governing wakefulness. Its abuse and dependence potential is lower than amphetamines but genuinely present, which is why it is a scheduled drug, and its adverse-effect profile still includes nervousness, anxiety, insomnia and appetite reduction. It is not a nootropic in the sense of making a rested brain smarter; it is a drug that makes a tired brain perform closer to its rested baseline.

Trial evidence exists for maintaining alertness and attention in sleep-deprived people (military and medical-shift studies). In well-rested users, meta-analyses show modest benefits to attention and executive function on longer, complex tasks — smaller than the hype implies, and near zero for simple tasks. It does not add capacity; it mostly restores what fatigue takes.

• Approved to improve wakefulness in adults with excessive sleepiness associated with narcolepsy, shift-work disorder or obstructive sleep apnoea. It does not treat the sleep apnoea itself — the label calls it adjunctive and says the underlying obstruction should still be treated.
• In sleep-deprived people, repeated trials show restored alertness and sustained attention — the effect is real and reasonably large when sleep debt is the problem.
• In rested, healthy adults the picture is much thinner. A meta-analysis of 19 placebo-controlled trials found only a small overall effect, and no significant difference between cognitive domains — the widely repeated "works on complex tasks" pattern comes from a qualitative review rather than pooled data. Effects on working memory and creativity are inconsistent.
• No trial supports it as an IQ or general-intelligence enhancer. One sleep-deprivation study reported that confidence rose more than measured performance; that is a single finding, not an established pattern in rested users.

Half-life around 12-15 hours in most people, which is why an afternoon dose can still be interfering with sleep at midnight. It is metabolised in the liver and induces CYP3A4, the enzyme that clears a large share of prescription drugs, which is the source of its most important interaction. Armodafinil is the longer-lasting single-isomer version. Detection in standard workplace drug screens is uncommon because it is not an amphetamine, though it is detectable on tests that specifically look for it, and it is banned in sport.

Headache, anxiety, insomnia, appetite suppression are common. Rare but serious: severe skin reactions (Stevens-Johnson syndrome) — the reason it carries warnings. Interacts with hormonal contraceptives (reduces effectiveness). Long half-life (~12–15 h) wrecks sleep when taken late, which quietly cancels the benefit. Dependence risk is low but not zero.

• Anyone relying on hormonal contraception without adding a non-hormonal method
• Anyone with a history of serious drug rash, or who develops any rash on it
• Anyone with significant cardiovascular disease, arrhythmia or uncontrolled hypertension
• Anyone with a history of psychosis, mania or bipolar disorder
• Anyone pregnant or breastfeeding — pregnancy registry data has raised congenital malformation signals

• Hormonal contraception — modafinil induces CYP3A4 and can reduce the effectiveness of the pill, patch, ring and implant. This is the single most consequential interaction and it causes real unintended pregnancies. It is standard advice to use an additional non-hormonal method during use and for a month after stopping.
• Other CYP3A4 substrates, a very long list that includes some immunosuppressants, antivirals and statins — levels can fall.
• Warfarin — monitoring is advised as levels can shift.
• Caffeine and other stimulants — additive cardiovascular effects and additive sleep disruption.
• Alcohol — poorly characterised, commonly reported as an unpleasant combination.

• Sleep — the most important thing to watch. Modafinil borrows alertness against sleep debt, and the debt still comes due.
• Blood pressure and heart rate, which can rise modestly.
• Skin — any rash is a stop-and-seek-care event, not a wait-and-see one, because of the rare severe cutaneous reactions.
• Serious psychiatric reactions are on the label and are not limited to low mood: mania, delusions, hallucinations, aggression and suicidal ideation have all been reported, and are reasons to stop and seek help rather than to push through.
• Multisystem hypersensitivity as well as severe rash — angioedema, anaphylaxis and DRESS are labelled reactions alongside Stevens-Johnson syndrome.
• For anyone using hormonal contraception, whether an alternative method is in place.

The controlled trial behind the label found no characteristic withdrawal syndrome beyond a return of sleepiness. Fatigue or sleepiness recurring is the common experience, though the popular explanation that this is purely repaid sleep debt is not something the evidence establishes. Abuse and dependence have been reported. Anyone who has been using it daily to sustain a work pattern usually finds the underlying sleep problem was never addressed, and that is the thing worth taking to a doctor.

US: Schedule IV prescription drug — legal only with a prescription. Frequently purchased from overseas pharmacies, which is unlawful importation and quality-uncontrolled.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial
  CNS Drugs, 2024
• Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial
  Lancet Neurol, 2024
• Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine
  Psychopharmacology (Berl), 2021

• Modafinil2006
• Modafinil, an atypical CNS stimulant?Adv Pharmacol · 2024
• Modafinil for poststroke patients: A systematic reviewInt J Clin Pract · 2019
• Modafinil2026
• Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain InjuryInnov Clin Neurosci · 2018
• Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic ReviewNeurocrit Care · 2020
• Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority TrialCNS Drugs · 2024
• Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-AnalysisSubst Use Misuse · 2017
• Modafinil-associated psychosis: a systematic review of case characteristics and management strategiesTher Adv Psychopharmacol · 2026
• Modafinil: a review of neurochemical actions and effects on cognitionNeuropsychopharmacology · 2008
• A review on modafinil: the characteristics, function, and use in critical careJ Drug Assess · 2020
• Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic reviewEur Neuropsychopharmacol · 2015